🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "significant breakthrough" in the fight against increasingly resistant strains of the bacteria, according to researchers.

A Worldwide Challenge

Gonorrhoea infections are increasing globally, with data suggesting more than 82 million instances per year. Particularly high rates are observed in the African continent and nations within the WHO's designated area, which includes Mongolia and China to New Zealand. In England, cases have reached a all-time high, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune advancement in the face of rising global incidence, the spread of superbugs and the highly restricted therapeutic options at this time.”

Medical experts are increasingly worried about the rise in drug-resistant strains. The World Health Organization has classified it as a "high-priority threat". Ongoing monitoring found that resistance to standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Drugs Gain Authorization

Zoliflodacin, also known as a brand name, was approved by the US Food and Drug Administration in recent days for combating gonorrhoea. This infection can lead to significant complications, including infertility. Researchers hope that targeted use of this new drug will help delay the emergence of superbugs.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This drug, which is employed against UTIs, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment was the result of a new, not-for-profit approach for antibiotic development. The non-profit organisation GARDP collaborated with the drug firm its industry partner to develop it.

“This milestone represents a huge turning point in the management of highly resistant gonorrhoea, which until now has been evolving faster than medical innovation.”

Research Study Data and Global Access

According to data published in a major medical journal, the new drug successfully treated over nine in ten of uncomplicated infections. This places it at an comparable level with the typical regimen, which combines two antibiotics. The study enrolled hundreds of patients from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, GARDP has the ability to make available and distribute the drug in numerous developing nations.

Clinicians on the front lines have voiced hope. Access to a easy-to-administer therapy such as this is described as a "critical tool" for managing the epidemic. This is viewed as vital to lessen the impact of the disease for patients and to halt the transmission of extremely resistant gonorrhoea worldwide.